Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Total Renal Research Inc

Neither a doctor nor a teaching hospital

Research payments

$19,365,018

6,741 payments

Through program year 2025, Total Renal Research Inc is reported as receiving $19,365,018 in research payments, across 6,741 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $106,484 19
2024 Research $440,477 49
2023 Research $981,055 49
2022 Research $2,703,746 41
2021 Research $5,811,254 856
2020 Research $4,863,123 739
2019 Research $4,458,879 4,988

Breakdown

Who paid Research payments · program years 2019–2025
  1. Akebia Therapeutics Inc $8,462,470 6,220 payments
  2. AstraZeneca Pharmaceuticals LP $6,204,049 81 payments
  3. AstraZeneca UK Limited $2,892,393 47 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $546,614 45 payments
  5. Baxter Healthcare $338,425 27 payments
  6. GlaxoSmithKline, LLC. $305,254 61 payments
  7. Retrophin, Inc. $300,494 200 payments
  8. Otsuka Pharmaceutical Development & Commercialization, Inc. $123,686 15 payments
  9. Alexion Pharmaceuticals, Inc. $77,834 3 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $65,348 38 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061) for Pre-exposure Prophylaxis of COVID-19 $7,342,391 47 payments
  2. Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (Dd-Ckd) (Inno2vate-Conversion) $3,679,761 455 payments
  3. Akb-6548-Ci-0017 $2,717,019 3,417 payments
  4. A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment $678,196 5 payments
  5. Akb6548ci0017 $571,034 767 payments
  6. A Phase 2b Multicenter Randomised Double blind Placebo controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricemia $448,093 41 payments
  7. Akb6548ci0016 $427,508 495 payments
  8. Akb-6548-Ci-0017 $397,153 681 payments
  9. A Phase 2b Randomised, Double-Blind, Placebo-Controlled, Multi-Centre, Dose-Ranging Study of AZD5718 in Participants with Proteinuric Chronic Kidney Disease $359,309 8 payments
  10. BI 685509 Dose finding PoCC in DKD $322,532 27 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $238,055 160 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record